JANX

Insider Trades

Name	Value	Action	Price	Current Price
Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr $57k4.1k shares SellJun 2, 2026 $14.03 --
Dobek MariaVice President, Accounting $29k2k shares SellMay 11, 2026 $14.17 --
Campbell David AlanDirector, Officer: President And CEO $111k8.1k shares SellJan 2, 2026 $13.73 --
McIver ZachariahChief Medical Officer $37k2.7k shares SellJan 2, 2026 $13.73 --
DiRaimondo ThomasChief Scientific Officer $34k2.5k shares SellJan 2, 2026 $13.73 --
Meyer Andrew HollmanChief Business Officer $26k1.9k shares SellJan 2, 2026 $13.73 --

News

zacks.comWall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Knowzacks.comMay 28

zacks.comHere's Why You Should Add JANX Stock to Your Portfolio Nowzacks.comMay 26

zacks.comJanux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 7

businesswire.comJanux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlightsbusinesswire.comMay 7

zacks.comHow Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%zacks.comMay 7

Trade JANX

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

CEO: David Alan Campbell
IPO Date: Jun 11, 2021

Market Data

Open: $14.33
High: $14.48
Low: $13.79
Volume: 1M
Avg Volume: 1M
52W High: $35.34
52W Low: $12.12

Valuation

Market Cap: $867M
Enterprise Value: $837M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-83M
Revenue: $10M
Net Income: $-114M
Cash: $52M
Debt: $22M

Events

EarningsAug 6

EPS est. -0.31